Immuron Ltd ADR (IMRN) - Total Assets
Based on the latest financial reports, Immuron Ltd ADR (IMRN) holds total assets worth $15.12 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Immuron Ltd ADR balance sheet independence to measure how much of total assets are equity-financed.
Immuron Ltd ADR - Total Assets Trend (2001–2025)
This chart illustrates how Immuron Ltd ADR's total assets have evolved over time, based on quarterly financial data. Explore Immuron Ltd ADR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Immuron Ltd ADR - Asset Composition Analysis
Current Asset Composition (June 2025)
Immuron Ltd ADR's total assets of $15.12 Million consist of 98.9% current assets and 1.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.1% |
| Accounts Receivable | $791.39K | 7.8% |
| Inventory | $1.77 Million | 17.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Immuron Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Immuron Ltd ADR (IMRN) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immuron Ltd ADR's current assets represent 98.9% of total assets in 2025, an increase from 71.0% in 2001.
- Cash Position: Cash and equivalents constituted 28.1% of total assets in 2025, up from 3.9% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 17.6% of total assets.
Immuron Ltd ADR Competitors by Total Assets
Key competitors of Immuron Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Immuron Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.04 | 6.80 | 55.64 |
| Quick Ratio | 6.83 | 5.92 | 54.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.06 Million | $10.03 Million | $26.80 Million |
Immuron Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Immuron Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.69 |
| Latest Market Cap to Assets Ratio | 0.64 |
| Asset Growth Rate (YoY) | -35.1% |
| Total Assets | $10.09 Million |
| Market Capitalization | $6.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Immuron Ltd ADR's assets below their book value (0.64x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Immuron Ltd ADR's assets decreased by 35.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Immuron Ltd ADR (2001–2025)
The table below shows the annual total assets of Immuron Ltd ADR from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $10.09 Million | -35.10% |
| 2024-06-30 | $15.55 Million | -29.28% |
| 2023-06-30 | $21.99 Million | -11.54% |
| 2022-06-30 | $24.86 Million | -8.12% |
| 2021-06-30 | $27.05 Million | +336.19% |
| 2020-06-30 | $6.20 Million | -27.56% |
| 2019-06-30 | $8.56 Million | -7.37% |
| 2018-06-30 | $9.24 Million | +11.54% |
| 2017-06-30 | $8.29 Million | -6.13% |
| 2016-06-30 | $8.83 Million | +46.67% |
| 2015-06-30 | $6.02 Million | -21.14% |
| 2014-06-30 | $7.63 Million | +202.07% |
| 2013-06-30 | $2.53 Million | -30.55% |
| 2012-06-30 | $3.64 Million | +36.77% |
| 2011-06-30 | $2.66 Million | -29.96% |
| 2010-06-30 | $3.80 Million | +670.42% |
| 2009-06-30 | $493.03K | -74.05% |
| 2008-06-30 | $1.90 Million | -42.36% |
| 2007-06-30 | $3.30 Million | -50.25% |
| 2006-06-30 | $6.63 Million | -17.75% |
| 2005-06-30 | $8.05 Million | +64.06% |
| 2004-06-30 | $4.91 Million | -25.35% |
| 2002-06-30 | $6.58 Million | -16.02% |
| 2001-06-30 | $7.83 Million | -- |
About Immuron Ltd ADR
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more